Skip to main content

Table 1 Serum neutralization titers to CVA13, CVA15 and CVA18.

From: Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18

Sample group No. sera No. CVA13-positive (%) No. CVA15-positive (%) No. CVA18-positive (%) No. CVA21-positive (%)
Commercial immune globulin 2 0 (0) 0 (0) 0 (0) 2 (100)
Melanoma 15 0 (0) 0 (0) 0 (0) 3 (20.0)
Control 6 0 (0) 0 (0) 0 (0) 0 (0.0)
Total patients 21 0 0 0 3 (14.3)
  1. Fifteen melanoma patients were examined for serum neutralization of CVA21, CVA13, CVA15 and CVA18. Heat inactivated serum samples were diluted serially, and then titrated against 100 TCID50 (CVA21, CVA13, CVA15 and CVA18) to assess neutralization status. Fifty percent neutralization scores of 1:4 or above calculated by the Karber method [19], were considered to be positive for neutralization status. Six healthy volunteers were also assessed for serum neutralizing antibodies against CVA13, CVA15 and CVA18, all of which were below 1:4 (50% neutralization score). Two commercially available immune serum globulin samples were also tested for neutralizing capacity.